Oct 9 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX
* Successfully held pre-Investigational New Drug meeting with FDA for its acne treatment product, BTX 1503
* Gained confirmation from FDA on overall drug development plan required for BTX 1503 to support New Drug Application